4.8 Article

Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy

Journal

NATURE NANOTECHNOLOGY
Volume 17, Issue 12, Pages 1332-+

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41565-022-01245-7

Keywords

-

Funding

  1. Susan G. Komen Foundation Career Catalyst Research Grant [CCR19605871]
  2. National Cancer Institute [1K08 CA241070]
  3. Department of Defense [W81XWH-19-1-0325]
  4. Cancer Center Support (Core) Grant from the National Cancer Institute, National Institutes of Health [P30 CA016672]

Ask authors/readers for more resources

Compared to hematological tumors, solid tumors have a lower response to immunotherapies. In this study, the authors propose a strategy to enhance the effectiveness of immunotherapies for solid tumors by decorating the cell membrane with a protein that promotes phagocytosis of cancer cells.
Solid tumours are less responsive to immunotherapies than haematological tumours due to specific biological differences. In this paper the authors propose a strategy to decorate the cell membrane of solid tumours with a protein typically present on haematological tumour cells that promotes phagocytosis of cancer cells, and show that this results in an increased immunotherapy efficacy in animal models of solid tumours. Solid tumours display a limited response to immunotherapies. By contrast, haematological malignancies exhibit significantly higher response rates to immunotherapies as compared with solid tumours. Among several microenvironmental and biological disparities, the differential expression of unique immune regulatory molecules contributes significantly to the interaction of blood cancer cells with immune cells. The self-ligand receptor of the signalling lymphocytic activation molecule family member 7 (SLAMF7), a molecule that is critical in promoting the body's innate immune cells to detect and engulf cancer cells, is expressed nearly exclusively on the cell surface of haematologic tumours, but not on solid ones. Here we show that a bispecific nanobioconjugate that enables the decoration of SLAMF7 on the surface of solid tumours induces robust phagocytosis and activates the phagocyte cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) pathway, sensitizing the tumours to immune checkpoint blockade. Our findings support an immunological conversion strategy that uses nano-adjuvants to improve the effectiveness of immunotherapies for solid tumours.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available